Holen Sie sich die Stockscreener-App
19.38
3.49%
-0.70
Schlusskurs vom Vortag:
$20.08
Offen:
$20.16
24-Stunden-Volumen:
784.27K
Relative Volume:
0.60
Marktkapitalisierung:
$1.54B
Einnahmen:
$288.00K
Nettoeinkommen (Verlust:
$-228.06M
KGV:
-4.56
EPS:
-4.25
Netto-Cashflow:
$-168.82M
1W Leistung:
+5.04%
1M Leistung:
+1.10%
6M Leistung:
+15.01%
1J Leistung:
+0.68%
1-Tages-Spanne:
$19.33
$20.27
1-Wochen-Bereich:
$17.96
$20.42
52-Wochen-Spanne:
$11.40
$27.20
Viridian Therapeutics Inc Stock (VRDN) Company Profile
Firmenname
Viridian Therapeutics Inc
Sektor
Branche
Telefon
617.272.4600
Adresse
221 CRESCENT STREET, WALTHAM
Vergleichen Sie VRDN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VRDN
Viridian Therapeutics Inc
|
19.38 | 1.54B | 288.00K | -228.06M | -168.82M | -4.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-11-25 | Eingeleitet | TD Cowen | Buy |
| 2024-09-11 | Bestätigt | Needham | Buy |
| 2024-06-11 | Eingeleitet | Wolfe Research | Outperform |
| 2024-06-06 | Eingeleitet | Goldman | Buy |
| 2024-05-09 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2024-05-09 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2023-06-14 | Eingeleitet | BTIG Research | Buy |
| 2023-06-14 | Fortgesetzt | Credit Suisse | Outperform |
| 2023-05-30 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-04-17 | Eingeleitet | Wells Fargo | Overweight |
| 2023-03-30 | Eingeleitet | Stifel | Buy |
| 2022-12-19 | Eingeleitet | Cowen | Outperform |
| 2022-12-19 | Eingeleitet | Needham | Buy |
| 2022-12-16 | Eingeleitet | Credit Suisse | Outperform |
| 2022-12-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-06-23 | Eingeleitet | B. Riley Securities | Buy |
| 2021-11-18 | Eingeleitet | SVB Leerink | Outperform |
| 2021-10-12 | Eingeleitet | Evercore ISI | Outperform |
| 2021-01-25 | Eingeleitet | Ladenburg Thalmann | Buy |
Alle ansehen
Viridian Therapeutics Inc Aktie (VRDN) Neueste Nachrichten
Short Interest in Viridian Therapeutics, Inc. (NASDAQ:VRDN) Grows By 28.9% - MarketBeat
SG Americas Securities LLC Raises Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat
SG Americas Securities LLC Has $596,000 Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
Viridian Therapeutics Stock Hits 3-Week High, Retail Buzz Builds On Chronic Thyroid Eye Disease Trial Data - MSN
Moody Aldrich Partners LLC Acquires Shares of 58,688 Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat
Equities Analysts Offer Predictions for VRDN Q1 Earnings - Defense World
Graves Ophthalmopathy Market to Expand Significantly by 2034, States DelveInsight Report | Novartis, AdvanceCor, Apitope, Worg Pharma, AV7 Limited - The Globe and Mail
What is Leerink Partnrs’ Estimate for VRDN FY2029 Earnings? - Defense World
Equities Analysts Issue Forecasts for VRDN Q1 Earnings - MarketBeat
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
(VRDN) Long Term Investment Analysis - Stock Traders Daily
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Leerink Partnrs Weighs in on VRDN FY2029 Earnings - MarketBeat
Viridian Therapeutics sees stock soar after Phase III TED success - MSN
Viridian Stock Flashes A Bullish Sign In Its Eye-Disease Battle With Amgen - MSN
Viridian Therapeutics (NASDAQ:VRDN) Trading Up 6.3%What's Next? - MarketBeat
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Sees Significant Growth in Short Interest - MarketBeat
JPMorgan Chase & Co. Purchases 274,641 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
JPMorgan Chase & Co. Raises Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat
Viridian Therapeutics (NASDAQ:VRDN) Earns “Buy” Rating from Needham & Company LLC - Defense World
Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease - BioSpace
Viridian Therapeutics, Inc. Promotes Seth Harmon to the Role of Chief Financial Officer - Marketscreener.com
(VRDN) Investment Analysis - Stock Traders Daily
Acelyrin To Take Tepezza Competitor Into Phase III In TED - Citeline News & Insights
Viridian Therapeutics (NASDAQ:VRDN) Shares Up 5.8%Here's Why - MarketBeat
Expert Outlook: Viridian Therapeutics Through The Eyes Of 10 Analysts - Benzinga
Viridian Therapeutics (NASDAQ:VRDN) Earns Buy Rating from Needham & Company LLC - MarketBeat
Analysts Set Viridian Therapeutics, Inc. (NASDAQ:VRDN) Price Target at $35.70 - MarketBeat
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Principal Financial Group Inc. Acquires 162,665 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
Principal Financial Group Inc. Boosts Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat
Geode Capital Management LLC Grows Stock Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat
Geode Capital Management LLC Has $33.98 Million Stock Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
Is Viridian Therapeutics, Inc. (NASDAQ:VRDN) Worth US$19.3 Based On Its Intrinsic Value? - Yahoo Finance
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Purchased by Barclays PLC - Defense World
Barclays PLC Boosts Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat
Viridian Therapeutics (NASDAQ:VRDN) Trading Down 3.4%What's Next? - MarketBeat
Contrasting Viridian Therapeutics (NASDAQ:VRDN) and Zicix (OTCMKTS:ZICX) - Defense World
Is Viridian Therapeutics, Inc. (NASDAQ:VRDN) Worth US$18.7 Based On Its Intrinsic Value? - Simply Wall St
Wells Fargo Downgrades Viridian Therapeutics (VRDN) - MSN
Viridian Therapeutics (NASDAQ:VRDN) Shares Gap DownTime to Sell? - MarketBeat
Viridian: Positive Chronic TED Data Likely To Lead To BLA Filing In Second Half Of 2025 (Rating Upgrade) - Seeking Alpha
Wells Fargo & Company Reiterates "Equal Weight" Rating for Viridian Therapeutics (NASDAQ:VRDN) - MarketBeat
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Sold by State Street Corp - Defense World
State Street Corp Has $54.14 Million Stock Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat
This C3.ai Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday - Benzinga
Viridian Therapeutics: Veligrotug De-Risked In TED With Hints Of Differentiation - Seeking Alpha
Viridian stock soars 25% on Phase 3 data for veligrotug - MSN
When (VRDN) Moves Investors should Listen - Stock Traders Daily
Viridian Therapeutics (NASDAQ:VRDN) Trading Down 5.7%Here's What Happened - MarketBeat
Breaking Down Viridian Therapeutics: 10 Analysts Share Their Views - Benzinga
Finanzdaten der Viridian Therapeutics Inc-Aktie (VRDN)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.95%
2.39%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):